Senti Biosciences Inc (NASDAQ: SNTI) is a clinical-stage cell and gene therapy company that develops gene circuit technologies designed to control therapeutic activity in response to disease biomarkers. The company has no product revenue, operating instead on collaboration agreements and partnership arrangements with external parties. Senti's core technology platform centers on programmable gene circuits, including Logic Gating constructs such as NOT GATE and OR GATE designs, intended to improve the precision of cancer cell killing while protecting healthy tissue. The company's lead program, SENTI-301A, was the subject of a Phase 1 investigator-initiated trial conducted by Celest Therapeutics in mainland China, which ceased enrollment in April 2025 following dose-limiting toxicities. Manufacturing is handled through a framework agreement with GeneFab, amended in December 2024 to include Valere Bio Inc. The company operates in a pre-commercial stage with no approved products as of the filing date of the FY2025 10-K filed March 27, 2026.

Revenue model

Senti Biosciences generates no product revenue. Its funding model relies on collaboration and option agreements with partners such as Celest Therapeutics. The company has not disclosed royalty, milestone, or upfront payment amounts supported by the available filing excerpts.

Products and services

Gene circuit platform including Logic Gating technology: NOT GATE circuits designed to protect healthy cells by recognizing protective antigens; OR GATE circuits designed to address tumor heterogeneity by targeting multiple antigens. Lead product candidate: SENTI-301A, a gene circuit applied to oncology. Manufacturing is conducted through an arrangement with GeneFab under an amended and restated development and manufacturing services agreement (amended December 2024).

Customers and end markets

End market is oncology, specifically cancer cell therapy. Collaboration partners include Celest Therapeutics (Shanghai) Co. Ltd., which conducted a Phase 1 investigator-initiated trial of SN301A in mainland China. No commercial customers disclosed in the filing excerpts.

Value-chain role

Senti sits at the research and development stage of the cell and gene therapy value chain, designing gene circuit technology and licensing or collaborating for clinical development. Manufacturing is outsourced to GeneFab. The company provides technical support to collaborators conducting clinical trials.

Geographic exposure

Operations primarily in the United States. Clinical trial activity conducted in mainland China through the Celest Therapeutics collaboration. The company states it conducts studies in Asia and is subject to data privacy regimes across multiple jurisdictions including the EU, UK, Brazil, Australia, Canada, and China.

Source: SEC 10-K, filed 2026-03-27

Industry: Biological Products, (No Diagnostic Substances) Peers: X4 Pharmaceuticals Inc Atreca, Inc. ZEO ScientifiX Inc Curis Inc Korro Bio Inc Disc Medicine Inc ImmuCell Corp Pyxis Oncology Inc Surface Oncology, Inc.